FRI0182 A Single Dose Study Comparing Pharmacokinetics, Safety, and Immunogenicity of M923 (A Proposed Biosimilar To Adalimumab), US-Sourced Adalimumab, and EU-Sourced Adalimumab in Healthy Subjects

Abstract

BackgroundM923 is being developed as a biosimilar to the reference product HUMIRA® (adalimumab). An extensive panel of tests were used to characterize the physicochemical, functional, and in vivo attributes to...